Raft MB, Hetland ML, Brahe CH, Horslev-Petersen K, et al. Serum 14-3-3eta as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial. Scand J Rheumatol 2022 Jul 14:1-11. doi: 10.1080/03009742.2022.2087900.
PMID: 35833274